TeamDrive
RUS

Interdepartmental Commission has approved NovaMedicas application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility

22 December 2017

Moscow, December 22, 2017 – Russian pharmaceutical company NovaMedica (investment project of Rusnano) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility. 

Portfolio of drug products which was supported by the IDC includes essential drugs which were transferred to NovaMedica within its partnership with Pfizer as well as own development products of NovaMedica. SPIC envisages extension of this list with the development of the pipeline of own R&D products of NovaMedica subject to approval of the IDC. Company plans to manufacture more than 40 modern effective drug products which are demanded by the Russian patients. 

“Creation of a greenfield high-tech pharmaceutical manufacturing facility in full compliance with international standards of quality will allow us to provide Russian patients with effective drug products and will open an opportunity to export our products abroad. SPIC is highly important for us. We greatly appreciate support of the Ministry of Industry and Trade of the Russian Federation and Administration of the Kaluga region where our plant is going to be constructed as well as of our strategic partner – Pfizer which transfers to us valuable knowledge and technologies of manufacturing of modern highly-demanded drug products”, noted Alexander Kuzin, CEO of NovaMedica

SPIC will include main measures of stimulation of development of pharmaceutical manufacturing in Russia by providing the status of local manufacturer as well as of the right to receive the status of unique supplier of a wide range of essential drug products in order to participate in the process of state procurement. Term of the SPIC is until 2026. It is planned that the Contract will be signed in the next couple of months. 

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica possesses a well-developed infrastructure for promotion and sales of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects. In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In October 2017 R&D Center of NovaMedica received a manufacturing license from the Ministry of industry and Trade of the Russian Federation. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.

More information at www.novamedica.com, follow us on Facebook and LinkedIn.


Previous publication Next publication

Media Center

  • 20 June 2018

    First Russian intradermal implant obtained registration

    The first Russian intradermal implant has successfully passed the state registration. This product has been developed over the past three years with the support of the Russian Ministry of Industry and Trade as part of the state policy of import substitution.

  • 20 June 2018

    EEC changed rules for registration of vaccines and use of GMP certificates

    The Council of the Eurasian Economic Commission (EEC) has amended the rules for registration and expert examination of medicinal products for human use in the Eurasian Economic Union. In particular, it adopted common approaches to the procedure for changing the registration documents for flu prevention vaccines.

  • 19 June 2018

    Russia is ready to supply insulin to Bulgaria

    The time has come to reduce imports from abroad and start establishing contacts with neighbors,” said Ivan Zarubin, acting Trade Representative of the Russian Federation in the Republic of Bulgaria, speaking at the Medicine and Pharmacy 2018, a Bulgarian-Russian business forum held in Sofia on June 13.

  • 19 June 2018

    Construction of a new pharmaceutical plant started in Usolye-Sibirskoye

    An official ceremony marking the launch of construction was held at the site of future plant for active pharmaceutical substances and finished medicinal products of Pharmasyntez-Chemie in Usolye-Sibirskoye on June 15.

Read more